Heterogeneity of genomic evolution and mutational profiles in multiple myeloma
2014 · Nature Communications · 890 citations
https://doi.org/10.1038/ncomms3997
T
Thierry Façon
Inserm(FR)
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
953
Papers
61.6K
Citations
113
h-index
443
i10-index
Thierry Façon is an academic researcher from Inserm. The author has contributed to research in topics: Multiple Myeloma Research and Treatments & Protein Degradation and Inhibitors & Cancer Treatment and Pharmacology. The author has an h-index of 113, co-authored 811 publications.
ORCID: 0000-0001-7705-8460Papers by this author
worksTreatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group
2021 · The Lancet Oncology · 257 citations
https://doi.org/10.1016/s1470-2045(20)30756-7
A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial
2019 · Leukemia · 221 citations
https://doi.org/10.1038/s41375-019-0539-0
IMWG consensus on maintenance therapy in multiple myeloma
2012 · Blood · 194 citations
https://doi.org/10.1182/blood-2011-11-374249
Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study
2018 · Clinical Lymphoma Myeloma & Leukemia · 89 citations
https://doi.org/10.1016/j.clml.2018.06.018
Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial
2024 · Nature Medicine · 87 citations
https://doi.org/10.1038/s41591-024-03050-2
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat